Novartis has a second positive phase 3 trial in the bag for its targeted factor B inhibitor iptacopan, vying to become an oral alternative to injectable therapies for ultra-rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH). The Swiss pharma group said…
ImmunoGen and Gilead Team Up to Target AML
ImmunoGen entered into a clinical collaboration deal with Gilead Sciences Friday to evaluate the safety and efficacy of two drugs that, when used in concert, have the potential to treat AML, a blood disorder biopharma has found challenging to target. …
US FDA grants clearance to commence trials of Sorrento’s mRNA vaccine
The microneedle system, along with an mRNA vaccine candidate, showed enhanced humoral immunity in animal models. The US Food and Drug Administration (FDA) has granted clearance to Sorrento Therapeutics to commence clinical trials of the messenger ribonucleic acid (mRNA) vaccine STI-1557. Targeting…
Phanes and BeiGene partner for advanced solid tumour therapy trial
The trial will assess the combination of Phanes’ PT199 and BeiGene’s tislelizumab to treat advanced solid tumours. Phanes Therapeutics has signed a clinical supply agreement with BeiGene for assessing a PT199 and tislelizumab combination in a Phase I clinical trial…
Health Canada grants CTA authorisation for QurAlis’ ALS therapy
Assessing the safety and tolerability of varying doses of QRL-201 in ALS patients is the primary objective of the trial. Health Canada has granted authorisation for the clinical trial application (CTA ) of QurAlis for the Phase I ANQUR trial of its…
